OrthoPediatrics (NASDAQ:KIDS) Price Target Raised to $30.00

OrthoPediatrics (NASDAQ:KIDS) had its price objective increased by Needham & Company LLC from $26.00 to $30.00 in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Canaccord Genuity Group started coverage on shares of OrthoPediatrics in a report on Wednesday, December 10th. They issued a “buy” rating and a $24.00 price target for the company. Wall Street Zen downgraded shares of OrthoPediatrics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Finally, TD Cowen raised OrthoPediatrics to a “strong-buy” rating in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.44.

OrthoPediatrics Trading Up 7.8%

KIDS opened at $19.17 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.52 and a current ratio of 7.40. The stock’s 50 day moving average price is $17.64 and its 200-day moving average price is $18.13. OrthoPediatrics has a one year low of $15.28 and a one year high of $26.40. The stock has a market cap of $480.78 million, a price-to-earnings ratio of -11.34 and a beta of 1.07.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.11. The company had revenue of $61.61 million during the quarter, compared to analysts’ expectations of $61.27 million. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.68%. On average, equities analysts forecast that OrthoPediatrics will post -0.93 EPS for the current year.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its stake in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after buying an additional 1,139 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after acquiring an additional 2,561 shares during the last quarter. Caption Management LLC purchased a new position in OrthoPediatrics in the third quarter worth approximately $54,000. BNP Paribas Financial Markets increased its stake in OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the last quarter. Finally, State of Wyoming increased its stake in OrthoPediatrics by 189.7% during the fourth quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after acquiring an additional 4,467 shares during the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Q4 beat — OrthoPediatrics reported EPS of ($0.26) vs. consensus ($0.37) and revenue of $61.61M vs. $61.27M, a combination that surprised the market to the upside. Earnings Release
• Positive Sentiment: Needham raised its price target to $30 and reiterated a Buy — the new target implies material upside versus the current share level and likely supported buying interest. Benzinga
• Positive Sentiment: BTIG also raised its target to $24 and kept a Buy rating, adding further analyst support to the stock move. Benzinga
• Positive Sentiment: Company reiterated 2026 revenue guidance of $262M–$266M and described an accelerating “product innovation super‑cycle,” which management frames as a multi‑year growth driver. Seeking Alpha
• Neutral Sentiment: Investor access: OrthoPediatrics announced participation in upcoming investor conferences, which should help management communicate the growth story but is not material on its own. GlobeNewswire
• Neutral Sentiment: Analyst/media coverage and detailed call notes/transcript are circulating (earnings transcript and coverage from Yahoo, Zacks, Seeking Alpha), which helps investors parse the quarter. Yahoo Finance
• Negative Sentiment: Profitability remains a concern — OrthoPediatrics is still loss‑making (negative net margin ~20% and negative ROE), and consensus expects negative full‑year EPS, which limits valuation multiple expansion until sustained profit improvement. Zacks

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.